samedan logo
 
 
 
spacer
home > pmps > summer 2020 > hand sanitiser labelling and covid-19 interim regulations
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Hand Sanitiser Labelling and COVID-19 Interim Regulations

The current coronavirus (COVID-19) pandemic has had a global impact on peopleís health and well-being. In the fight against the virus, the importance of using hand sanitisers and surface disinfectants has become the focus towards preventing and eliminating the spread of the virus. Specifically, the use of alcohol-based sanitisers for consumers and healthcare settings has been shown to be beneficial in combating the spread of the virus; this, in turn, has created regulatory and labelling challenges. This is a time when manufacturers, suppliers, and distributors are looking for ways to market their sanitiser products quickly and effectively, while still meeting the regulatory requirements for the country or region the product is being sold to.

In response to the virus, many countries have implemented revised labelling requirements for the sale and distribution of sanitiser products and have allowed some exceptions to their current regulations and processes. The focus is to allow companies to quickly market sanitisers that will meet the requirements for quality, effectiveness, and safety for use against the virus, while still following the necessary labelling guidelines. The best way to prevent the spread of the virus and to decrease Alison Senyi at Nexreg Compliance the chance of getting sick is for people to wash their hands with soap and water. As an alternative, the Centers for Disease Control and Prevention recommends that consumers should use an alcohol-based hand sanitiser that contains a minimum of 60% alcohol. Additionally, WHO has issued a guide for the production of recommended hand sanitiser formulations. In response to the unprecedented demand for these products, we will be discussing the country- specific requirements and regulations for hand sanitisers.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Alison Senyi is a Senior Regulatory Consultant at Nexreg Compliance, assisting with various labelling, and consulting projects. Alison finds the challenges of her regulatory role to be rewarding and enjoys taking an active part in bringing on new services to meet the ever-changing compliance needs of the industry. Prior to joining Nexreg in 2016, Alison completed a Bachelorís degree at the University of Ottawa and a Certificate of Occupational Safety and Health from Algonquin College, Canada. Her background in health and safety has given Alison a greater understanding of the hazards of chemical products, which motivates her to promote awareness about chemical safety and compliance.
spacer
Alison Senyi at Nexreg Compliance
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Leading pharma packaging companies commit to supply for Covid-19 fight

The CEOs of Gerresheimer, Stevanato Group, and SCHOTT are committed to ensuring ample supply of pharmaceutical containers for any Covid-19 vaccine and treatment that is developed, and that no patient shall be left behind, no matter what region of the world they live in. Also, the companies will make every effort to support the pharma industryísí priorities for overall medication supply in addition to Covid-19 drugs. Each of the three companies manufactures billions of type-1 borosilicate glass vials, the most proven and most widely available material used to store and deliver vaccines around the world. They are making the statement to provide confidence in the global pharmaceutical supply chain in times of uncertainty.
More info >>

White Papers

Achieve full compliance with tamper-verification pharma solutions

UPM Raflatac

UPM Raflatac has developed a range of pharmaceutical labelling products to support compliance with the Falsified Medicines Directive on packaging for prescription drugs and high-risk, over-the-counter medicines. Few solutions offer the same ease of adoption for meeting the February 2019 deadline.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement